Pediatrics

Projects

Projects per year 2006 2009 2014 2016 2017 2018 2020 2021 2022 2023 2024 2030

• 37 Active
• 91 Completed

Projects per year

Search results

• Active

  A Phase 2, Randomized, Double-Blind, Active-Controlled, Dose-Finding Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants Given 4 Doses at 2, 4, 6, and 12-15 Months of Age Concomitantly with Routine Pediatr

  Rupp, R. (PI)

  Vaxcyte Inc ( Award # )

  3/11/25 → 3/10/30

  Project: Research project

• Teen Health Award 2025-2027

  Rupp, R. (PI)

  Sealy and Smith Foundation ( Award # )

  1/1/25 → 12/31/27

  Project: Research project

• A MULTICENTER, OPEN-LABEL, PHASE 1B STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SULBACTAM-DURLOBACTAM IN HOSPITALIZED PEDIATRIC PATIENTS FROM BIRTH TO <18 YEARS WHO ARE RECEIVING SYSTEMIC ANTIBIOTIC THERAPY FOR SUSPECTED OR CONFIRM

  Aigbivbalu, L. (PI)

  Entasis Therapeutics ( Award # )

  12/23/24 → 12/22/29

  Project: Research project

• A Phase 1, Randomized, Double-Blind, Comparator-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540A in Healthy Adults

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  10/30/24 → 10/29/29

  Project: Research project

• A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V118 Formulation C in Healthy Adults

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  8/27/24 → 8/26/28

  Project: Research project

• A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 4-arm study to investigate the mixed vaccination schedules of a 21-valent pneumococcal conjugate vaccine and a 20-valent pneumococcal conjugate vaccine in healthy infants an

  Rupp, R. (PI)

  Sanofi Pasteur, Inc ( Award # )

  7/19/24 → 7/18/29

  Project: Research project

• A PHASE 2, RANDOMIZED, PARTIALLY DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF AMULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE ADMINISTERED IN HEALTHY TODDLERS 12 THROUGH 15 MONTHS OF AGE

  Rupp, R. (PI)

  Pfizer, Inc ( Award # )

  7/15/24 → 7/14/29

  Project: Research project

• Protein Cargo and Antiviral Properties of Epithelial-derived EVs in RSV Infection

  Corsello, T. (PI)

  Parker B. Francis Fellowship Program ( Award # )

  7/1/24 → 6/30/27

  Project: Research project

  • Antiviral Properties 100%
  • RSV Infection 100%
  • Protein Cargo 100%
  • Extracellular Vesicles 100%
  • Antiviral Activity 100%

• EPAC1 as a Crucial Host Factor and Therapeutic Target of SARS-CoV-2

  Bao, X. (PI)

  American Lung Association - National ( Award #ERP-1252718)

  7/1/24 → 6/30/26

  Project: Research project

  • COVID-19 100%
  • Therapeutic Target 100%
  • Host Factors 100%
  • Epac1 100%
  • Severe Acute Respiratory Syndrome Coronavirus 2 100%

• A Phase 2, Randomized, Double-Blind Trial to Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Pneumococcal Conjugate Vaccine In Healthy Infants

  Rupp, R. (PI)

  Pfizer, Inc ( Award # )

  6/28/24 → 6/27/27

  Project: Research project

• Extracellular Vesicles (EVs) Innate Immune Cargo in Respiratory Viral Infections

  Garofalo, R. P. (PI)

  National Institute of Allergy and Infectious Diseases ( Award #1R21AI17608501A1)

  6/18/24 → 4/30/26

  Project: Research project

  • Antivirus Agent 100%
  • Viral Respiratory Tract Infection 100%
  • Viral Disease 100%
  • Human Respiratory Syncytial Virus 100%
  • Airway 100%

• Pilot DSHS Newborn Screening

  Cooney, E. (PI)

  Texas Department of State Health Services ( Award #HHS001417100002)

  6/17/24 → 8/31/28

  Project: Research project

• Phase III, randomized, single-blind, placebo-controlled, multi-center study to evaluate non-interference of concomitant administration of routine pediatric vaccines on the antibody response of an investigational live-attenuated respiratory syncytial viru

  Rupp, R. (PI)

  Sanofi Pasteur, Inc ( Award # )

  5/8/24 → 5/7/29

  Project: Research project

• A Phase 3, Randomized, Observer-Blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza in Healthy Individuals

  Rupp, R. (PI)

  Pfizer, Inc ( Award # )

  11/15/23 → 11/14/28

  Project: Research project

• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Immunogenicity of V181 Dengue Quadrivalent Vaccine rDENV30 live, attenuated in Healthy Adults 59 Years of Age or Older

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  10/17/23 → 10/16/28

  Project: Research project

• DMID Program Planning Agreement - Next Generation Covid-19 Vaccine Development Program

  Rupp, R. (PI)

  Leidos Biomedical Research, Inc ( Award #75N91019D00024)

  8/18/23 → 12/31/25

  Project: Research project

• Role of Airway Derived Extracellular Vesicles (EVs) in Respiratory Viral Infections

  Corsello, T. (PI)

  American Lung Association - National ( Award #CA1040556)

  7/1/23 → 12/31/25

  Project: Research project

  • Respiratory Viral Infection 100%
  • Airway 100%
  • Extracellular Vesicles 100%
  • Viral Respiratory Tract Infection 100%
  • Lung 100%

• A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V117 Formulation C in Healthy Adults

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  6/28/23 → 6/27/28

  Project: Research project

• Role of Hypoxia-Inducible Factors (HIFs) in Respiratory Syncytial Virus Infection

  Casola, A. (PI)

  National Institute of Allergy and Infectious Diseases ( Award #5R21AI17595502)

  6/16/23 → 8/31/25

  Project: Research project

  • Hypoxia-inducible Factor 100%
  • Respiratory Syncytial Virus Infection 100%
  • Hypoxia Inducible Factor 100%
  • Hypoxia-inducible factor-1α (HIF-1α) 66%
  • Clinical Disease 50%

• tRNA-derived RNA Fragments (tRF) as Prognostic and Diagnostic Biomarkers for Alzheimer¿s Disease

  Bao, X. (PI)

  National Institute on Aging ( Award #5R61AG07572503)

  3/15/23 → 2/28/26

  Project: Research project

• A MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BIVALENT BNT162b2 RNA -BASED VACCINE CANDIDATE(S) IN HEALTHY CHILDREN

  Rupp, R. (PI)

  Pfizer, Inc ( Award # )

  2/22/23 → 2/21/28

  Project: Research project

• PIWIL4 and piRNAs in RSV Infection

  Casola, A. (PI)

  National Institute of Allergy and Infectious Diseases ( Award #5R21AI17166402)

  1/25/23 → 8/31/25

  Project: Research project

• Protocol No. C5261001: A Phase 1 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza in Healthy Individuals

  Rupp, R. (PI)

  Pfizer, Inc ( Award # )

  1/24/23 → 1/23/28

  Project: Research project

• Biogenesis and Function of tRNA-derived RNA Fragments in Alzheimer's Disease: Novel Biomarkers

  Bao, X. (PI)

  Darrell K. Royal Research Fund for Alzheimer's Disease ( Award # )

  9/1/22 → 8/31/26

  Project: Research project

• A Phase 1/2a Open-Label Dose-Ranging and Observer-Blind Placebo-Controlled, Safety and Immunogenicity Study of mRNA-1647 Cytomegalovirus Vaccine in Female and Male Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

  Rupp, R. (PI)

  Moderna Therapeutics, Inc ( Award # )

  8/30/22 → 8/29/27

  Project: Research project

• The SIP Study: Simultaneously Implementing Pathways for Improving Asthma, Pneumonia, and Bronchiolitis Care for Hospitalized Children (75581 sponsor award # change)

  Sweeney Gotsch, B. (PI)

  University of California - San Francisco ( Award #5R33HL15780404)

  7/5/22 → 6/30/25

  Project: Research project

• tRNA-derived RNA Fragments and their Role in Nasal SARS-COVID-2 Infection

  Bao, X. (PI)

  National Institute of Allergy and Infectious Diseases ( Award #5R21AI16654302)

  7/1/22 → 6/30/26

  Project: Research project

• A Phase IIb, Randomized, Observer-Blind study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

  Rupp, R. (PI)

  GlaxoSmithKline Pharmaceuticals ( Award # )

  2/14/22 → 2/13/27

  Project: Research project

• A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

  Rupp, R. (PI)

  ModernaTX, Inc ( Award # )

  2/11/22 → 2/10/27

  Project: Research project

• A Phase 1/2, First-Time-in Human (FTiH), randomized, observer-blind, placebo-controlled, dose escalation study to assess safety, reactogenicity and immunogenicity of a candidate cytomegalovirus (CMV) vaccine comprising recombinant protein and adjuvant wh

  Rupp, R. (PI)

  GlaxoSmithKline Pharmaceuticals ( Award # )

  11/12/21 → 11/11/26

  Project: Research project

• A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  10/19/21 → 10/18/26

  Project: Research project

• A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients from 1 Year to Less than 18 Years Old Hospitalized with COVID-19

  Aigbivbalu, L. (PI)

  Eli Lilly ( Award # )

  10/1/21 → 9/30/26

  Project: Research project

• PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTH

  Rupp, R. (PI)

  Pfizer, Inc ( Award # )

  3/29/21 → 3/28/26

  Project: Research project

• A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  1/29/21 → 1/28/26

  Project: Research project

• A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen with Extended Dosing Intervals in 9- to 14-Year Old Boys and Girls Compared with a Standard 3-dose Regimen

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  12/22/20 → 12/21/25

  Project: Research project

• A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo- controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistencvbcvbcvbcvbcvbcvbcbcbcbcb

  Rupp, R. (PI)

  Merck Sharp and Cohme Corporation ( Award # )

  12/12/19 → 12/11/26

  Project: Research project

• Admin Core

  Garofalo, R. P. (PI)

  National Institute of Allergy and Infectious Diseases ( Award #5P01AI06288515)

  7/25/18 → 6/30/25

  Project: Research project

• Completed

  Multicenter Network of Neonatal Intensive Care Units-University of Houston (UT Houston) Clinical Center

  Jain, S. (PI)

  University of Texas Health Science Center - Houston ( Award #1U24HD09525401)

  4/1/23 → 3/31/24

  Project: Research project

• Phase 2 Randomized, Open-Label, Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox

  Rupp, R. (PI)

  Leidos Biomedical Research, Inc ( Award #75N91019D00024)

  3/28/23 → 3/31/25

  Project: Research project

• Phase 2 Clinical Trial to Optimize Immune Coverage of SARS-CoV-2 Existing and Emerging Variants (short title, COVID-19 Adaptive Variant Immunologic Landscape Trial (COVAIL Trial)

  Rupp, R. (PI)

  Leidos Biomedical Research, Inc ( Award #5UM1AI14868403)

  3/31/22 → 7/30/24

  Project: Research project

  • Immunogenomic Landscape 100%
  • Emerging Variants 100%
  • COVID-19 100%
  • Phase II Clinical Trial 100%
  • Immune Coverage 100%

• Translational studies of the fecal microbiome associated with BIAFAC

  Pyles, R. (PI)

  Glenn Greenberg and Linda Vester Foundation ( Award # )

  1/1/22 → 12/31/24

  Project: Research project

• A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) after Receipt of EUA Vaccines

  Rupp, R. (PI)

  Baylor College of Medicine ( Award #3UM1AI14857503S2)

  7/14/21 → 11/30/24

  Project: Research project

• A Phase 3 Randomized, Observer-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Lyophilized Formulation of the Vaccine Candidate BNT162b2 Against COVID-19 in Healthy Adults 18 through 55 years of Age.

  Rupp, R. (PI)

  Pfizer, Inc ( Award # )

  3/11/21 → 3/10/25

  Project: Research project

• A PHASE 3, SINGLE-ARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE

  Rupp, R. (PI)

  Pfizer, Inc ( Award # )

  1/4/21 → 1/3/23

  Project: Research project

• IMPAACT Leadership Group-PTCL 03

  Rupp, R. (PI)

  Johns Hopkins University ( Award #5UM1AI06863217)

  12/1/20 → 11/30/23

  Project: Research project

• Innate Inhibitory Activity and Anti-SARS-CoV-2 Antibodies in Human Milk

  Garofalo, R. P. (PI)

  Gerber Foundation ( Award # )

  11/20/20 → 11/19/23

  Project: Research project

• tRNA-derived RNA Fragments, A New Regulator for Alzheimer's Disease

  Bao, X. (PI)

  National Institute on Aging ( Award #5R21AG06922601)

  9/15/20 → 8/31/24

  Project: Research project

• Fellow: Aline Haas de Mello; Role of Endogenous Hydrogen Sulfide and Trans-sulfuration Pathway in Antiviral T cell Immunity

  Garofalo, R. P. (PI)

  American Association of Immunologists ( Award # )

  9/1/20 → 8/31/21

  Project: Research project

• Vaccine and Treatment Evaluation Units (VTEU)- COVID Supplement

  Rupp, R. (PI)

  Baylor College of Medicine ( Award #3UM1AI14857503S6)

  7/13/20 → 11/30/23

  Project: Research project

• A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose Finding Study To Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of SARS-CoV-2 RNA Vaccine Candidates against COVID 19 in Healthy Adults

  Rupp, R. (PI)

  Pfizer, Inc ( Award # )

  6/19/20 → 6/18/24

  Project: Research project